CompanyARVNNasdaqNew Haven, CT

Arvinas Inc.

Arvinas develops PROTAC protein degrader therapies targeting disease-causing proteins.

SEC EDGAR ClinicalTrials.gov arvinas.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 6Latest story

August 2026

Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumors

Aug 6Trial updateARV-6723 Arvinas Inc.

Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drug

Aug 4Quarterly updateArvinas Inc.